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Background: Our objective was to study the long-term effects of non-invasive positive
pressure ventilation (NPPV) on lung function and gas exchange in patients with the obesity
hypoventilation syndrome (OHS).
Design: Prospective observational study in OHS patients performing NPPV over a period of
24 months.
Results: We studied 35 clinically stable OHS patients with a mean body mass index (BMI)
45.978.8 kg/m2 and daytime PaCO2 at room air of 6.9270.48 kPa at baseline. Nocturnal
NPPV was initiated with pressure-cycled devices on IPAP 2473 cm H2O, EPAP 672 cm H2O
and respiratory frequency of 18.873.7/min. After 12 and 24 months of NPPV hypercapnia
was persistently normalized and hypoxemia was markedly improved while no changes in
calculated alveolar–arterial oxygen difference occurred. Augmented ventilation was
followed by a significant reduction in hemoglobin and hematocrit (Po0.001 each). Daily
duration of ventilator use significantly correlated with the decrease in PaCO2 after 12
months (r ¼ 0.37; Po0.05) and 24 months (r ¼ 0.47; Po0.05). Vital capacity (VC) and
expiratory reserve volume (ERV) significantly increased after 12 and 24 months NPPV
compared to the baseline values, though BMI was only slightly reduced. The 2-year survival
rate was 91% with three patients (9%) discontinuing NPPV during the study period.
Conclusion: Long-term domiciliary NPPV normalizes hypercapnia and markedly improves
hypoxemia as well as polycythemia in OHS patients. In addition, NPPV leads to a significant
reduction in restrictive ventilatory disturbance, predominantly by increasing ERV.Elsevier Ltd. All rights reserved.
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& 2006 Elsevier Ltd. All rights reserved.Introduction
Obesity hypoventilation syndrome (OHS), formerly described
as ‘‘Pickwickian syndrome’’, is defined by chronic alveolar
hypoventilation during wakefulness (PaCO246.0 kPa,
PaO2o9.3 kPa breathing room air) in obese patients with a
body mass index (BMI)430 kg/m2.1,2 In order to confirm the
diagnosis of OHS, other pulmonary, thoracic, metabolic or
neuromuscular diseases accounting for the gas anomalies
should be excluded.3 OHS is usually associated with
obstructive sleep apnea and pulmonary hypertension. Major
clinical features are hypersomnolence, dyspnea and head-
ache in combination with polycythemia, cyanosis and right
heart failure.2
Obesity is a worldwide increasing health burden, reaching
epidemic proportions in some countries.3,4 Nevertheless,
OHS is under-recognized and under-treated. One reason for
frequent inadequate treatment with bronchospasmolytics or
steroids5 may be that OHS patients often present with
unspecific symptoms. Acute hypercapnic decompensation
often happens to be the cause for diagnosing OHS on the
intensive care unit.6
The pathophysiologic relationship between obesity and
hypoventilation is not yet fully understood. Currently the
complex interactions between increased work of breathing,
abnormal central ventilatory control, hyperleptinemia and
sleep-disordered breathing are being discussed.7 Compared
to similarly obese individuals without daytime hypercapnia,
patients with OHS have significantly impaired respiratory
system mechanics with a restrictive ventilatory pattern.5
In addition to alveolar hypoventilation, also ventilation–
perfusion mismatching secondary to pulmonary atelectasis8
contributes to hypoxemia in OHS.
Non-invasive positive pressure ventilation (NPPV) has
been successfully used in the treatment of respiratory
failure in patients with OHS.9–12 However, data regarding
the long-term effects of nocturnal NPPV and underlying
mechanisms in patients with the OHS are scarce. From a
pathophysiologic view, NPPV may exert its beneficial effects
at least partly by lung recruitment. Therefore we hypothe-
sized, that augmented ventilation and improved gas
exchange following NPPV treatment is associated with a
reduction of restrictive ventilatory pattern in OHS.Methods
Patient selection
All patients with OHS in whom home mechanical ventilation
(HMV) with NPPV was successfully initiated at the DonaustaufHospital, Germany, from January 1999 to May 2004 were
prospectively evaluated for eligibility for the study. The
inclusion criteria were as follows: Obesity-hypoventilation
syndrome with BMI 430 kg/m2, daytime hypercapnia while
breathing room air (PaCO246.0 kPa), clinical symptoms of
chronic ventilatory insufficiency, i.e. hypersomnolence, morn-
ing headache, fatigue, dyspnea and elective initiation of NPPV
in a stable clinical situation. Patients with clinical signs of
acute respiratory airway infection, acute hypercapnic decom-
pensation, respiratory acidosis (pHo7.35) or left ventricular
decompensation as well as patients with tracheostomy and
those who were switched from invasive ventilation to NPPV
after acute hypercapnic respiratory failure were excluded
from the study. Furthermore, patients with significant
obstructive ventilatory disorder (FEV1/VCino65% of predicted
value) and those with other pulmonary, thoracic or neuro-
muscular disorders leading to hypoventilation were not
included in the study. The study was approved by the
University of Regensburg ethics committee.
As current work suggests that NPPV has a positive impact
on mortality in OHS, we deemed it not ethical to include a
control group without NPPV in our study.
Measurements
All patients underwent standardized medical evaluations
including anthropometric data, pulmonary function tests,
inspiratory muscle function, blood gas analysis and routine
laboratory parameters. Measurements were performed
before initiation of NPPV and after 12 and 24 months. Body
weight was measured after cardial recompensation in case
of right heart failure. Whole bodyplethysmography (Master-
lab, Jaeger Inc., Wu¨rzburg, Germany) was performed
following the guidelines of the American Thoracic Society
in a sitting position.13 The reference values were those of
the European Community for Steel and Coal.14 Inspiratory
mouth occlusion pressure at 100ms (P0.1) and maximal
inspiratory mouth pressure (PImax) were measured as
described previously.15 Blood gas parameters (Rapidlab,
Bayer Inc., East Walpole, MA, USA) were measured from the
hyperemic earlobe during daytime spontaneous breathing of
room air. The alveolar–arterial oxygen difference (A–aDO2)
was calculated using the approximate formula: 20-
PaO21.25 PaCO2.16 During follow-up, blood gas analysis
was performed in the morning, approximately 4 h after
nocturnal NPPV. Ventilator settings after initiation of NPPV
were recorded, including ventilation mode, type of venti-
lator and mask, inspiratory positive airway pressure (IPAP),
expiratory positive airway pressure (EPAP) and respiratory
frequency. Duration of ventilator use was calculated by the
time counter indicator on the ventilator.
ARTICLE IN PRESS
Table 1 Anthropometric data, blood gas analysis, hemoglobin, hematocrit at baseline and after 12 and 24 months NPPV.
Characteristic Baseline 12 months 24 months
n 35 32 30
Male/female (%) 66/34
Age (yr) 55.8711.1
Body mass index (kg/m2) 45.978.8 44.779.2ns 43.978.2ns
pH 7.4270.04 7.4470.05** 7.4470.03ns
PaCO2 (kPa) 6.9270.48 5.5570.82* 5.4570.68
ns
PaO2 (kPa) 6.6870.83 8.4871.24* 8.6771.15
ns
BE (mmol/l) 9.576.7 3.372.2* 3.172.3ns
A–a gradient (kPa) 4.770.9 4.671.0ns 4.571.3ns
Hb (g/l) 157722 139715* 137714ns
Hc (%) 48.076.9 40.974.3* 40.373.6ns
Values are presented as mean7SD. Wilcoxon test for dependent values. Values at 12 months were compared to baseline values. Values
at 24 months were compared to 12 month values.
*Po0.001; **Po0.05; ns ¼ not significant.
Non-invasive positive pressure ventilation improves lung volumes in the obesity hypoventilation syndrome 1231NPPV technique
NPPV was routinely applied via commercial nasal or full-face
masks (nasal mask Gold Seal or Special, Respironics Inc.,
Murrysville, PA, USA and NV Ultra Mirage nasal or full face
mask; ResMed Inc., North Ryde, Australia). Custom-made
masks were only applied in cases of persistent leakage and/
or nasal ulceration. NPPV was usually started in the pressure
support mode; after a phase of adaptation it was switched
to a pressure-cycled assist-control mode. EPAP was set to
overcome upper airway obstruction, IPAP was gradually
increased to augment ventilation, targeting a normalization
of PaCO2. Oxygen was supplemented to achieve oxygen
saturation 490% only when necessary after an increase in
effective inspiratory pressure (IPAPEPAP) as far as toler-
ated by the patient.
Statistical analysis
Data were collected in a data bank (Microsoft Accesss) and
were analyzed with the SPSS software package (SPSS,
version 12.0; Chicago, IL, USA). The non-parametric
Wilcoxon test for dependant variables was used for changes
in functional parameters and blood gases at two different
time points. P-valueso0.05 were considered significant.
Correlations between changes in lung volumes, blood gas
parameters and ventilator use were assessed using a linear
regression model (Pearson correlation). Results are pre-
sented as mean values7standard deviation (SD).
Results
Anthropometric characteristics
Fifty-nine patients with OHS starting HMV with NPPV were
evaluated for the study: 9 patients were excluded because
of clinical instability at the start of HMV, 8 patients were
excluded because of significant obstructive airway disease,
1 patient was lost to follow-up and 6 patients were excludedbecause of missing data. Thirty-five patients with OHS
fulfilled the inclusion criteria and were successfully adapted
to HMV: 12 female (34%) and 23 male (66%), mean age
55.8711.1 years, BMI 45.978.8 kg/m2 (Table 1). At follow-
up after 12 and 24 months NPPV, there was no significant
change in BMI compared to baseline values. Two patients
could be switched from NPPV to CPAP therapy under
polysomnographic control after 8 and 14 months following
massive weight reduction.
Blood gas analysis
Blood gas analysis prior to the initiation of NPPV during
daytime spontaneous breathing of room air revealed
pronounced hypoxemia and hypercapnia with metabolic
compensated respiratory acidosis. Follow-up at 12 and 24
months after initiation of NPPV showed a normalization of
PaCO2 during daytime spontaneous breathing of room air,
accompanied by a considerable improvement in hypoxemia
and a significant reduction in base excess (Table 1).
There were no changes in calculated alveolar–arterial
oxygen difference.
Polycythemia
Follow-up showed a significant decrease in polycythemia
parallel to the improvement in hypoxemia (Table 1). The
same result was found in the subgroup of 15 patients without
additional oxygen therapy (Po0.05).
Polysomnography
Polysomnography (PSG) was performed in 31 patients (89%)
prior to the initiation of NPPV. According to former studies
on OHS the cut-off point for diagnosing obstructive sleep
apnea was set at an apnea-hypopnea-index (AHI)X20/h
(10,19). In 22 patients (71% of the patients with PSG), OHS
was associated with significant obstructive sleep apnea:
mean AHI 66727/h, mean arterial oxygen saturation (SaO2)
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without concomitant obstructive sleep apnea was found: AHI
8.9+6.1/h, mean SaO2 76.977.3%.
NPPV technique
Mean IPAP was 2473 cm H2O, mean EPAP was 672 cm H2O,
preset mean respiratory frequency was 18.873.7/min.
Additional long-term oxygen therapy was initiated in 20
patients (57%), mean oxygen flow 1.0771.09 l/min.
Adherence to NPPV and mortality
Two patients (6%) discontinued NPPV within the 24-month
period (1 in the first and 1 in the second year). Three OHS
patients (9%) died within the 24-month period, (2 in the first
and 1 in the second year). The causes of death were
(1 patient each): car accident, hepato-renal syndrome and
multiple organ failure, massive pulmonary embolism.
For this reason, follow-up at 12 and 24 months could be
performed in 32 and 30 patients, respectively. A lack of
compliance, defined by daily ventilator use of less than 3 h,
was observed in 4 patients (11%) during the first year and 2
patients during the second year. In patients showing
adequate adherence to therapy, duration of ventilator use
was 6.271.8 h and 6.871.7 h per day during the first 2
years.
We found a significant correlation between the daily
duration of ventilator use with the decrease in PaCO2 after
12 months (r ¼ 0.37; Po0.05) and 24 months (r ¼ 0.47;
Po0.05) (Fig. 1). But no correlation could be demonstrated
between daily ventilator use and change in base excess.
Pulmonary function tests
Before initiation of NPPV, pulmonary function tests showed a
restrictive ventilatory defect with a slight reduction in total
lung capacity (TLC) and a more pronounced reduction in
vital capacity (VC) (Table 2). Residual volume related to
total lung capacity (RV/TLC) was increased, while intrathor-
acic gas volume (ITGV) proved to be within normal ranges0 4 8 10 12
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Figure 1 Correlation between daily duration of NPPV and
change in PaCO2 at 12 months (r ¼ 0.37; Po0.05)and expiratory reserve volume (ERV) was considerably
reduced. Forced expiratory volume in 1 s (FEV1) was
diminished as a consequence of restrictive ventilatory
defect, and according to the inclusion criteria, there was
no significant bronchial obstruction: FEV1 related to VCin
99.3710.1% of predicted value.
Follow-up after 12 months NPPV revealed a normalization
of restrictive ventilatory defect with a significant increase in
TLC, VC and a significant reduction in RV/TLC (Table 2).
ERV showed a marked increase while IC was found to be
slightly increased without statistical significance (Fig. 2).
Follow-up after 24 months NPPV showed no further changes
in pulmonary function tests compared to 12 months.Discussion
In this prospective study we examined the long-term effects
of domiciliary NPPV in a large group of patients with the
OHS. This is the first study to demonstrate that NPPV leads
to a significant improvement in restrictive ventilatory
disorder in OHS and is followed by a marked decrease in
polycythemia, independently of weight change. The effec-
tiveness of NPPV is based on the application of high
inspiratory pressures and a high level of therapy adherence.
NPPV has already been shown to effectively improve
hypoventilation and daytime symptoms when used chroni-
cally in patients with OHS who fail therapy with continuous
positive airway pressure (CPAP).9–12 Lucas-Ramos and
coworkers found that the use of HMV in OHS is associated
with an increase in the ventilatory response to hypercapnic
stimulus.10 According to our results, in a recent study de
Llano et al.12 observed that the decrease in hypercapnia
after long-term NPPV is accompanied by a pronounced rise
in PaO2.
Hypoxemia in OHS results from both alveolar hypoventila-
tion and ventilation–perfusion mismatching, due to good
perfusion but considerable under-ventilation of dependent
regions of the lung.13 However, since we found no significant
long-term effects of NPPV on calculated alveolar–arterial
oxygen difference (gas exchange), our data do not support
that the improvement of hypoxemia in response to NPPV is
due to a reduction of ventilation–perfusion mismatching.
Augmented ventilation is accompanied by a considerable
decrease in secondary polycythemia, which is not depen-
dent on additional oxygen therapy. To our knowledge, this is
the first study showing that NPPV reduces significantly
hemoglobin and hematocrit in OHS patients. A study of
NPPV7oxygen therapy in patients with chronic respiratory
failure due to chronic obstructive pulmonary disease showed
similar effects on hematocrit.17
In obesity, the increased abdominal load shifts the
diaphragm on upward direction, thereby diminishing ERV.18
ERV is probably the most sensitive indicator of obesity on
pulmonary function.19 In contrast, the residual volume (RV)
is normal or slightly increased, because the mass loading of
chest wall with limited function of expiratory muscles as
well as high closing volume help to maintain RV even in
morbid obesity.3,20 TLC is described as being reduced,
indicating a mild restrictive ventilatory pattern, and RV
related to TLC is found to be higher than normal.
The decrease in FEV1 is in proportion to the change in
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Table 2 Pulmonary function tests at baseline and after 12 and 24 months NPPV.
Characteristic Baseline 12 months 24 months
n 35 32 30
TLC (% pred) 83.2716.7 94.9715.6* 92.3714.1ns
TLC (l) 4.971.4 5.771.4* 5.671.2ns
ITGV (% pred) 92.6723.2 106.1725.9** 103.6723.6ns
VC (l) 2.4870.85 3.0170.89* 2.9370.89ns
VC (% pred) 65.8715.3 81.9715.4* 80.5717.9ns
ERV (l) 0.4870.43 0.7370.56** 0.7370.55ns
IC (l) 2.0670.61 2.3170.67ns 2.2470.69ns
RV/TLC (%) 50.279.0 46.678.2** 46.878.7ns
FEV1 (% pred) 63.2716.3 79.1717.6* 77.5718.3
ns
FEV1/VC (%) 76.677.9 76.678.0
ns 76.479.9ns
FEV1/VC (% pred) 99.3710.1 98.9710.1
ns 99.2712.1ns
SRtot (kPa s) 1.8770.89 1.3870.58** 1.3370.50
ns
SRtot (% pred) 171.3794.9 126.8755.5** 122.5751.4
ns
P0.1 (kPa) 0.4270.32 0.3370.16
ns 0.3470.13ns
PImax (kPa) 5.1272.22 5.3272.59
ns 6.1272.42ns
Values are presented as mean7SD. Wilcoxon test for dependent values. Values at 12 months were compared to baseline values. Values
at 24 months were compared to 12 month values.
*Po0.001; **Po0.05; ns ¼ not significant.
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Figure 2 Changes in inspiratory capacity (IC), expiratory
reserve volume (ERV) and residual volume (RV) after 12 and
24 months NPPV.
Non-invasive positive pressure ventilation improves lung volumes in the obesity hypoventilation syndrome 1233FVC, so that the FEV1/FVC ratio in obesity usually remains
normal.21
In this study, we found a significant improvement in static
lung volumes in OHS patients as a consequence of long-term
NPPV. Interestingly, there was a marked increase in ERV, the
parameter which best characterizes the restrictive disorder
in obesity (Fig. 2). The increase in VC is mainly a result of
substantially augmented ERV, rather than heightened IC.
Excessive weight loss is known to result in significant
increases in lung volumes in patients with morbid obesity.22As BMI was only slightly reduced in our study, the reduction
of restrictive ventilatory defect is assumed to be due to a
decrease in the premature closure of dependent airways
during expiration and to an opening of microatelectasis,
leading to increased lung compliance.3,23,24
Increased respiratory resistance associated with obesity
has been suggested to result from the reduction of lung
volumes.25 Ferretti et al.26 additionally described expiratory
flow limitation in massively obese subjects, leading to
dynamic pulmonary hyperinflation and intrinsic positive end-
expiratory pressure. In this study, we found a significant
reduction in total specific resistance (SRtot) in OHS patients
treated with NPPV, as a consequence of the increase in lung
volumes.
In the literature, reports on changes of pulmonary
function after long-term NPPV in OHS are scarce and
contradictory.10–12 This could also be explained by the fact
that significant airway obstruction, and hence COPD, was
not excluded in other studies. Masa and coworkers did not
find any significant changes in FVC, FEV1 and TLC after
4 months NPPV, but in their group of 22 OHS patients, BMI
was lower and inspiratory pressures used for ventilation
were lacking.10 Our work confirms de Llano and coworkers
findings of markedly reduced VC and ERV before the start of
NPPV, but contrary to this study, their follow-up at 12
months demonstrated no significant improvement in lung
volumes. In their study mean IPAP was 1873 cm H2O, mean
EPAP 972 cm H2O.
12 However, in agreement with our
results, Lucas-Ramos described a significant increase in
FVC after 12 months of bilevel therapy.11
In the current study, NPPV was performed with bi-level
positive airway pressure devices in the assist-control mode.
The effective inspiratory pressure (IPAPEPAP) determines
the augmentation of alveolar ventilation and the recruit-
ment of collapsed alveolar spaces.24 In contrast to previous
studies, the effective inspiratory pressure necessary to
abolish hypoventilation in our OHS patients was considerably
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H2O were poorly tolerated by OHS patients.
12 The higher
level of ventilatory pressures might serve as an explanation
for the increase in lung volumes found in this study. Joris and
coworkers observed a ‘‘dose-dependent effect’’ of IPAP on
the pulmonary restrictive syndrome in postoperative obese
patients.22 The authors of the current study are convinced
that using too low pressures is a frequent cause of therapy
failure in NPPV.
In this study, we found a remarkably high compliance with
NPPV therapy during long-term follow-up over 24 months.
These data compare favorably with the study of Janssens
and coworkers.9 High adherence to nocturnal domiciliary
ventilation appears to be the foundation for effectiveness,
as daily ventilator use positively correlates with the
normalization of hypercapnia (Fig. 1).
In our study, mortality in OHS patients performing NPPV
was 9% within 24 months. Nowbar and coworkers described
in their prevalence study on hospitalized patients with
severe obesity, a population which appears to be quite
comparable to our study group.5 In their study, hypoventila-
tion was treated in only 13% of the patients. Mortality was
23% after 18 months, markedly higher than in our study with
9% mortality.Limitations
The results of our study are limited by the fact that we did
not perform control PSG at follow-up visits. EPAP settings
used may have been inadequate to maintain upper airway
patency, and this could be revealed by PSG, as demon-
strated in a recent study by Storre et al.28 In future studies
using the technique of high inspiratory pressures the
influence on sleep should be addressed. A further limitation
is constituted by the lack of measurements of maximal
expiratory pressures, as an impairment of expiratory muscle
function may be involved in the reduced ERV.
In this study, we focused on the positive impact of NPPV
on the restrictive ventilatory pattern in OHS. But this is only
one of the mechanisms that explain the beneficial role of
NPPV in these severely sick patients like respiratory muscle
rest, restoration of chemosensitivity and improved sleep
quality.Conclusion
Long-term domiciliary NPPV normalizes hypercapnia and
markedly improves hypoxemia as well as polycythemia in
OHS patients. In addition, NPPV leads to a significant
reduction in restrictive ventilatory disturbance, predomi-
nantly by increasing ERV. Application of high inspiratory
pressures and good adherence to therapy are presumed to
be the basis for the beneficial effects of NPPV in OHS.References
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